entertainment -WSS

entertainment

author：explore 2025-09-29 01:38:14 - browse：349

Johnson & Johnson sign — MARK RALSTON/AFP via Getty Images

WASHINGTON — Pharmaceutical giant Johnson & Johnson on Tuesday became the third drugmaker to sue the Biden administration over its new Medicare drug price negotiation program.

J&J joins a flurry of litigation challenging the Medicare drug price negotiation program, which is set to start this fall. Merck, Bristol Myers Squibb, the brand-drug lobby PhRMA, and the U.S. Chamber of Commerce have also filed suit. The negotiated prices would go into effect in 2026.

The company argued that it is entitled to sue because its blockbuster blood thinner drug Xarelto may be up for negotiation in the first round of ten drugs Medicare will examine, but that list is not set to be announced officially until Sept. 1.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Liquid biopsy for lung cancer is launched by Delfi

hotspot

focus

WSS

Fight over Supreme Court dialysis ruling puts kidney patients at risk

FDA rejects Alnylam's heart disease treatment over insufficient data

FDA panel signals lack of confidence in Amgen cancer drug data

Why Charlie Gard's case is so disturbing to Americans

A new initiative will help leaders fight the next pandemic

Sana to lay off nearly a third of staff, de

knowledge

entertainment

hotspot

Activists slam private health insurers over coverage restrictions

An outdated Medicare rule harms dementia patients with anxiety

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

Peter Hotez and the public health issue of online harassment

A new initiative will help leaders fight the next pandemic

Malaria cases in Florida and Texas: Here’s what you need to know

ASCO Daily Recap: CAR

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Sutter Health’s antitrust win overturned by appeals court

leisure time

FDA panel signals lack of confidence in Amgen cancer drug data

Congress needs to close a vaccine

Physician executives need more than on

https://cbu01.alicdn.com/img/ibank/2017/122/705/4468507221_1632892910.220x220xz.jpg

Phenylephrine and the overlooked value of the placebo effect

Why age limits for politicians are a terrible idea

hotspot

focus

focus

focus